Lithium but not carbamazepine augments antidepressant efficacy of mirtazapine in unipolar depression: An open-label study

World Journal of Biological Psychiatry

Volumn 10, Issue 4 PART 2, 2009, Pages 390-399

  Schle, Cornelius ^a   Baghai, Thomas C ^a   Eser, Daniela ^a   Nothdurfter, Caroline ^a   Rupprecht, Rainer ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Augmentation strategies; Carbamazepine; Lithium; Mirtazapine; Unipolar depression

Indexed keywords

ANTIDEPRESSANT AGENT; CARBAMAZEPINE; LITHIUM; MIRTAZAPINE; ANTICONVULSIVE AGENT; DRUG DERIVATIVE; LITHIUM CARBONATE; MIANSERIN; TRANQUILIZER; TRICYCLIC ANTIDEPRESSANT AGENT;

ADULT; AGED; ARTICLE; BIPOLAR DISORDER; CLINICAL ARTICLE; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DISEASE SEVERITY; DRUG EFFICACY; HAMILTON SCALE; HUMAN; MAJOR DEPRESSION; BIOAVAILABILITY; BLOOD; CLINICAL TRIAL; COMPARATIVE STUDY; DRUG COMBINATION; DRUG POTENTIATION; FEMALE; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED;

ADULT; AGED; ANTICONVULSANTS; ANTIDEPRESSIVE AGENTS, TRICYCLIC; ANTIMANIC AGENTS; BIOLOGICAL AVAILABILITY; CARBAMAZEPINE; DEPRESSIVE DISORDER, MAJOR; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; LITHIUM CARBONATE; MALE; METABOLIC CLEARANCE RATE; MIANSERIN; MIDDLE AGED; YOUNG ADULT;

EID: 77449153032     PISSN: 15622975     EISSN: 18141412     Source Type: Journal    
DOI: 10.1080/15622970701849978     Document Type: Article

References (99)

1. Ananth J. 1998. Treatment-resistant depression. Psychother. Psychosom. 67:61-70.
2. Ballenger JC. 1988. The clinical use of carbamazepine in affective disorders. J Clin Psychiatry 49 Suppl:13-21.
3. Ballenger JC, Post RM. 1980. Carbamazepine in manic-depressive illness: a new treatment. Am J Psychiatry 137:782-790.
4. Barbee JG, Jamhour NJ. 2002. Lamotrigine as an augmentation agent in treatment-resistant depression. J Clin Psychiatry 63:737-741.
5. Barbosa L, Berk M, Vorster M. 2003. A double-blind, randomized, placebo-controlled trial of augmentation with lamotrigine or placebo in patients concomitantly treated with fluoxetine for resistant major depressive episodes. J Clin Psychiatry 64:403-407
6. Bauer M. 1995. The combined use of lithium and SSRIs. J Serotonin Res 2:69-76.
7. Bauer M, Whybrow PC, Angst J, Versiani M, Moller HJ. 2002. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders, Part 1: Acute and continuation treatment of major depressive disorder. World J Biol Psychiatry 3: 5-13
8. Bauer M, Adli M, Baethge C, Berghofer A, Sasse J, Heinz A, et al. 2003a. Lithium augmentation therapy in refractory depression: clinical evidence and neurobiological mechanisms. Can J Psychiatry 48:440-448.
9. Bauer M, Forsthoff A, Baethge C, Adli M, Berghofer A, Dopfmer S, et al. 2003b. Lithium augmentation therapy in refractory depression-update 2002. Eur Arch Psychiatry Clin Neurosci 253:132-139.
10. Baumann P, Nil R, Souche A, Montaldi S, Baettig D, Lambert S, et al. 1996. A double-blind, placebo-controlled study of citalopram with and without lithium in the treatment of therapy-resistant depressive patients: a clinical, pharmacokinetic, and pharmacogenetic investigation. J Clin Psychophar-macol 16:307-314.
11. Bowden CL. 2005. A different depression: clinical distinctions between bipolar and unipolar depression. J Affect Disord 84:117-125.
12. Brosen K, Kragh-Sorensen P. 1993. Concomitant intake of nortriptyline and carbamazepine. Ther Drug Monit 15:258-260.
13. Bruijn JA, Moleman P, Mulder PG, van den Broek WW. 1998. Comparison of 2 treatment strategies for depressed inpatients: imipramine and lithium addition or mirtazapine and lithium addition. J Clin Psychiatry 59:657-663.
14. Bschor T, Bauer M. 2006. Efficacy and mechanisms of action of lithium augmentation in refractory major depression. Curr Pharm Des 12:2985-2992.
15. Bschor T, Adli M, Baethge C, Eichmann U, Ising M, Uhr M, et al. 2002. Lithium augmentation increases the ACTH and cortisol response in the combined DEX/CRH test in unipolar major depression. Neuropsychopharmacology 27:470-478
16. Calabrese JR, Markovitz PJ, Kimmel SE, Wagner SC. 1992. Spectrum of efficacy of valproate in 78 rapid-cycling bipolar patients. J Clin Psychopharmacol 12:53S-56S.
17. Calabrese JR, Bowden CL, McElroy SL, Cookson J, Andersen J, Keck PE, Jr., et al. 1999a. Spectrum of activity of lamotrigine in treatment-refractory bipolar disorder. Am J Psychiatry 156:1019-1023.
18. Calabrese JR, Bowden CL, Sachs GS, Ascher JA, Monaghan E, Rudd GD. 1999b. A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. Lamictal 602 Study Group. J Clin Psychiatry 60:79-88.
19. Ciusani E, Zullino DF, Eap CB, Brawand-Amey M, Brocard M, Baumann P. 2004. Combination therapy with venlafaxine and carbamazepine in depressive patients not responding to venlafaxine: pharmacokinetic and clinical aspects. J Psychopharmacol 18:559-566.
20. Coryell W 2000. Augmentation strategies for inadequate antidepressant response: a review of placebo-controlled studies. Ann Clin Psychiatry 12:141-146.
21. Cowen PJ, McCance SL, Ware CJ, Cohen PR, Chalmers JS, Julier DL. 1991. Lithium in tricyclic-resistant depression. Correlation of increased brain 5-HT function with clinical outcome. Br J Psychiatry 159:341-346.
22. Cullen M, Mitchell P, Brodaty H, Boyce P, Parker G, Hickie I, et al. 1991. Carbamazepine for treatment-resistant melancholia. J Clin Psychiatry 52:472-476.
23. Davis LL, Kabel D, Patel D, et al. 1996. Valproate as an antidepressant in major depressive disorder. Psychopharmacol Bull 32:647-652.
24. Davis LL, Bartolucci A, Petty F. 2005. Divalproex in the treatment of bipolar depression: a placebo-controlled study. J Affect Disord 85:259-266.
25. De la Fuente JM, Mendlewicz J. 1992. Carbamazepine addition in tricyclic antidepressant-resistant unipolar depression. Biol Psychiatry 32:369-374.
26. De Montigny C. 1994. Lithium addition in treatment-resistant depression. Int Clin Psychopharmacol 9 (Suppl 2):31-35.
27. De Montigny C, Grunberg F, Mayer A, Deschenes JP. 1981. Lithium induces rapid relief of depression in tricyclic antidepressant drug non-responders. Br J Psychiatry 138:252-256.
28. DeBattista C. 2006. Augmentation and combination strategies for depression. J Psychopharmacol 20:11-18.
29. DeVeaugh-Geiss J, Ascher J, Brook S, Cedrone J, Earl N, Emsley R, et al. 2000. Safety and tolerability of lamotrigine in controlled monotherapy trials in mood disorders. Presented at the 39th Annual ACNP Meeting, December 10-14, San Juan, Puerto Rico.
30. Dietrich DE, Emrich HM. 1998. The use of anticonvulsants to augment antidepressant medication. J Clin Psychiatry 59(Suppl 5):51-58.
31. Eap CB, Yasui N, Kaneko S, Baumann P, Powell K, Otani K. 1999. Effects of carbamazepine coadministration on plasma concentrations of the enantiomers of mianserin and of its metabolites. Ther Drug Monit 21:166-170.
32. Ebes F, Van Lookeren-Campagne AM, Hartmans HLA. 1998. A phase I, single center, single-blind, placebo-controlled multiple dose study of the interaction between Org 3770 and carbamazepine in healthy male volunteers. Study 22514, Report No. NL 0003854, Oss: N. V. Organon (Data on file).
33. Elphick M. 1989. Clinical issues in the use of carbamazepine in psychiatry: a review. Psychol Med 19:591-604.
34. Feiner NF 1997. Antiepileptic drug augmentation for treatment-resistant depression. J Clin Psychiatry 58:361-363.
35. Fogelson DL, Sternbach H. 1997. Lamotrigine treatment of refractory bipolar disorder. J Clin Psychiatry 58:271-273.
36. Freeman MP, Freeman SA. 2006. Lithium: clinical considerations in internal medicine. Am J Med 119:478-481
37. Frye MA, Ketter TA, Kimbrell TA, Dunn RT, Speer AM, Osuch EA, et al. 2000. A placebo-controlled study of lamotrigine and gabapentin monotherapy in refractory mood disorders. J Clin Psychopharmacol 20:607-614.
38. Gabriel A. 2006. Lamotrigine adjunctive treatment in resistant unipolar depression: an open, descriptive study. Depress. Anxiety 23:485-488
39. Hamilton M. 1960. A rating scale for depression. J Neurol Neurosurg Psychiatry 23:56-62.
40. Himmelhoch JM, Detre T, Kupfer DJ, Swartzburg M, Byck R. 1972. Treatment of previously intractable depressions with tranylcypromine and lithium. J Nerv Ment Dis 155:216-220.
41. Hirschfeld RM, Keller MB, Panico S, Arons BS, Barlow D, Davidoff F, et al. 1997. The National Depressive and Manic-Depressive Association consensus statement on the undertreatment of depression. JAMA 277:333-340. (Pubitemid 27045015)
42. Katona CL, Abou-Saleh MT, Harrison DA, Nairac BA, Edwards DR, Lock T, et al. 1995. Placebo-controlled trial of lithium augmentation of fluoxetine and lofepramine. Br J Psychiatry 166:80-86.
43. Keck PE, Jr., McElroy SL, Strakowski SM. 1998. Anticonvulsants and antipsychotics in the treatment of bipolar disorder. J Clin Psychiatry 59 (Suppl 6):74-81.
44. Ketter TA, Frye MA, Cora-Locatelli G, Kimbrell TA, Post RM. 1999. Metabolism and excretion of mood stabilizers and new anticonvulsants. Cell Mol Neurobiol 19:511-532.
45. Khan A, Shad MU, Preskorn SH. 2000. Lack of sertraline efficacy probably due to an interaction with carbamazepine. J Clin Psychiatry 61:526-527.
46. Kusumakar V, Yatham LN. 1997. An open study of lamotrigine in refractory bipolar depression. Psychiatry Res 72:145-148.
47. Laroudie C, Salazar DE, Cosson JP, Cheuvart B, Istin B, Girault J, et al. 2000. Carbamazepine-nefazodone interaction in healthy subjects. J Clin Psychopharmacol 20:46-53.
48. Laurenza A, Asnis G, Beaman M. 1999. A double-blind placebo-controlled study supporting the efficacy of lamotrigine in unipolar depression. Bipolar Disord 1:39-40
49. Leinonen E, Lepola U, Koponen H. 1996. Substituting carbamazepine with oxcarbazepine increases citalopram levels. A report on two cases. Pharmacopsychiatry 29:156-158.
50. Londborg PD, Cutler NR, Cunningham LA, Haines FX, Pahl JJ, West SA. 1999. A double-blind, placebo-controlled study suuporting the efficacy of lamotrigine in unipolar depression. Poster presented at the American Psychiatric Association Annual Meeting, May 15-20, Washington, DC. (SCAA2011 [613]).
51. Maltese TM. 1999. Adjunctive lamotrigine treatment for major depression. Am J Psychiatry 156:1833.
52. Martinelli V, Bocchetta A, Palmas AM, Del Zompo M. 1993. An interaction between carbamazepine and fluvoxamine. Br J Clin Pharmacol 36:615-616.
53. McIntyre RS, Mancini DA, McCann S, Srinivasan J, Sagman D, Kennedy SH. 2002. Topiramate versus bupropion SR when added to mood stabilizer therapy for the depressive phase of bipolar disorder: a preliminary single-blind study. Bipolar Disord 4:207-213.
54. Mendels J. 1976. Lithium in the treatment of depression. Am J Psychiatry 133:373-378.
55. Moustgaard G. 2000. Treatment-refractory depression successfully treated with the combination of mirtazapine and lithium. J Clin Psychopharmacol 20:268.
56. Nelson JC, Mazure CM. 1986. Lithium augmentation in psychotic depression refractory to combined drug treatment. Am J Psychiatry 143:363-366.
57. Nemeroff CB. 2000. An ever-increasing pharmacopoeia for the management of patients with bipolar disorder. J Clin Psychiatry 61 (Supp 13):19-25.
58. Nemets B, Bersudsky Y, Belmaker RH. 2005. Controlled double-blind trial of phenytoin vs. fluoxetine in major depressive disorder. J Clin Psychiatry 66:586-590.
59. Neumann J, Seidel K, Wunderlich H. 1984. Comparative studies of the effect of carbamazepine and trimipramine in depression. In: Emrich, HM, Okuma, T, Muller, AA (Eds.), Anticonvulsants in affective disorders Elsevier, Amsterdam, the Netherlands, pp. 160-166.
60. Nickel C, Lahmann C, Tritt K, Muehlbacher M, Kaplan P, Kettler C, et al. 2005. Topiramate in treatment of depressive and anger symptoms in female depressive patients: a randomized, double-blind, placebo-controlled study. J Affect Disord 87:243-252.
61. Nierenberg AA, Amsterdam JD. 1990. Treatment-resistant depression: definition and treatment approaches. J Clin Psychiatry 51 (Suppl):39-47
62. Normann C, Hummel B, Scharer LO, Horn M, Grunze H, Walden J. 2002. Lamotrigine as adjunct to paroxetine in acute depression: a placebo-controlled, double-blind study. J Clin Psychiatry 63:337-344.
63. O'Flanagan PM. 1973. Letter: Clomipramine infusion and lithium carbonate: a synergistic effect? Lancet 2:974.
64. Patsalos PN, Perucca E. 2003. Clinically important drug interactions in epilepsy: general features and interactions between antiepileptic drugs. Lancet Neurol 2:347-356. (Pubitemid 38352562)
65. Post RM, Uhde TW, Roy-Byrne PP, Joffe RT. 1986. Antidepressant effects of carbamazepine. Am J Psychiatry 143:29-34.
66. Prasad AJ. 1985. Efficacy of carbamazepine as an antidepressant in chronic resistant depressives. J Indian Med Assoc 83:235-237.
67. Rocha FL, Hara C. 2003. Lamotrigine augmentation in unipolar depression. Int Clin Psychopharmacol 18:97-99.
68. Rouillon F, Gorwood P. 1998. The use of lithium to augment antidepressant medication. J Clin Psychiatry 59 (Suppl 5): 32-39.
69. Rybakowski J, Matkowski K. 1992. Adding lithium to antidepressant therapy: factors related to therapeutic potentiation. Eur Neuropsychopharmacol 2:161-165.
70. Rybakowski JK, Suwalska A, Chlopocka-Wozniak M. 1999. Potentiation of antidepressants with lithium or carbamazepine in treatment-resistant depression. Neuropsychobiology 40: 134-139.
71. Schaffer CB, Mungas D, Rockwell E. 1985. Successful treatment of psychotic depression with carbamazepine. J Clin Psychopharmacol 5:233-235.
72. Schindler F, Anghelescu IG. 2007. Lithium versus lamotrigine augmentation in treatment resistant unipolar depression: a randomized, open-label study. Int Clin Psychopharmacol 22:179-182.
73. Schneier HA, Kahn D. 1990. Selective response to carbamazepine in a case of organic mood disorder. J Clin Psychiatry 51:485.
74. Schule C, Romeo E, Uzunov DP, et al. 2006. Influence of mirtazapine on plasma concentrations of neuroactive steroids in major depression and on 3alpha-hydroxysteroid dehydrogenase activity. Mol Psychiatry 11:261-272.
75. Schule C, Baghai TC, Di Michele F, et al. 2007. Effects of combination treatment with mood stabilizers and mirtazapine on plasma concentrations of neuroactive steroids in depressed patients. Psychoneuroendocrinology 32:669-680.
76. Sethi BB, Tiwari SC. 1984. Carbamazepine in affective disorders. In: Emrich,HM, Okuma,T, Muller,AA (Eds.), Anticonvulsants in affective disorders Elsevier, Amsterdam, the Netherlands, pp. 167-176.
77. Shapira B, Nemets B, Trachtenberg A, Belmaker RH. 2006. Phenytoin as an augmentation for SSRI failures: a small controlled study. J Affect Disord 96:123-126.
78. Sitsen JM, Voortman G, Timmer CJ. 2000. Pharmacokinetics of mirtazapine and lithium in healthy male subjects. J Psychopharmacol 14:172-176.
79. Souza FG, Goodwin GM. 1991. Lithium treatment and prophylaxis in unipolar depression: a meta-analysis. Br J Psychiatry 158:666-675.
80. Spina E, Avenoso A, Pollicino AM, Caputi AP, Fazio A, Pisani F. 1993. Carbamazepine coadministration with fluoxetine or fluvoxamine. Ther Drug Monit 15:247-250.
81. Spina E, Avenoso A, Campo GM, Caputi AP, Perucca E. 1995. The effect of carbamazepine on the 2-hydroxylation of desi-pramine. Psychopharmacology (Berl) 117:413-416
82. Sporn J, Sachs G. 1997. The anticonvulsant lamotrigine in treatment-resistant manic-depressive illness. J Clin Psychopharmacol 17:185-189.
83. Steinacher L, Vandel P, Zullino DF, Eap CB, Brawand-Amey M, Baumann P. 2002. Carbamazepine augmentation in depressive patients non-responding to citalopram: a pharmacokinetic and clinical pilot study. Eur Neuropsychopharmacol 12:255-260.
84. Stormer E, von Moltke LL, Shader RI, Greenblatt DJ. 2000. Metabolism of the antidepressant mirtazapine in vitro: contribution of cytochromes P-450 1A2, 2D6, and 3A4. Drug Metab Dispos 28:1168-1175.
85. Suppes T, Brown ES, McElroy SL, Keck PE, Jr., Nolen W, Kupka R, et al. 1999. Lamotrigine for the treatment of bipolar disorder: a clinical case series. J Affect Disord 53:95-98.
86. Timmer CJ, Sitsen JM, Delbressine LP. 2000. Clinical pharmacokinetics of mirtazapine. Clin Pharmacokinet 38:461-474
87. Tylee A, Gastpar M, Lepine JP, Mendlewicz J. 1999. DEPRES II (Depression Research in European Society II): a patient survey of the symptoms, disability and current management of depression in the community. DEPRES Steering Committee. Int Clin Psychopharmacol 14:139-151.
88. Van der Loos M, Nolen W. 2006. Lamotrigine as add-on to lithium in bipolar depression. Presented at the Fifth European Stanley Conference on Bipolar Disorder, Barcelona, October 5-7, 2006.
89. Walden J, Hesslinger B, Van Calker D, Berger M. 1996. Addition of lamotrigine to valproate may enhance efficacy in the treatment of bipolar affective disorder. Pharmacopsychiatry 29:193-195.
90. Winsberg ME, DeGolia SG, Strong CM, Ketter TA. 2001. Divalproex therapy in medication-naive and mood-stabilizer-naive bipolar II depression. J Affect Disord 67:207-212.
91. Wittchen HU, Wunderlich U, Zaudig M, Fydrich T 1997 (Strukturiertes Klinisches Interview fur DSM-IV Achse I: Psychische Storungen. [Structured clinical interview for DSM-IV, Axis I, German version]). Hogrefe, Gottingen.
92. Wunderlich H, Heim H, Wunderlich HP. 1982a. Carbamazepin (Finlepsin) bei endogenen affektiven Psychosen: eine neue Therapie. Medicamentum 60:2-8.
93. Wunderlich H, Neumann J, Grünes JU. 1982b. Carbamazepin (Finlepsin) bei manisch-depressiven Erkrankungen. Deutsches Gesundheitswesen 37:1471.
94. Wunderlich HP, Grunes JU, Neumann J, Zahlten W 1983. [Antidepressive therapy with carbamazepine (Finlepsin)]. Schweiz. Arch Neurol Neurochir Psychiatr 133:363-371.
95. Yatham LN, Kusumakar V, Parikh SV, Haslam DR, Matte R, Sharma V, et al. 1997. Bipolar depression: treatment options. Can. J Psychiatry 42 (Suppl 2):87S-91.
96. Yatham LN, Kennedy SH, O'Donovan C, Parikh S, MacQueen G, McIntyre R, et al. 2005. Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: consensus and controversies. Bipolar. Disord. 7 (Suppl 3):5-69.
97. Yatham LN, Kennedy SH, O'Donovan C, Parikh SV, MacQueen G, McIntyre RS, et al. 2006. Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: update 2007. Bipolar Disord 8:721-739.
98. Zall H, Therman PG, Myers JM. 1968. Lithium carbonate: a clinical study. Am J Psychiatry 125:549-555.
99. Zullino D, Baumann P. 2001. Lithium augmentation in depressive patients not responding to selective serotonin reuptake inhibitors. Pharmacopsychiatry 34:119-127.